Moberg Pharma AB (publ)

Stockholm Stock Exchange MOB.ST

Moberg Pharma AB (publ) Operating Income for the year ending December 31, 2023: USD -2.71 M

Moberg Pharma AB (publ) Operating Income is USD -2.71 M for the year ending December 31, 2023, a -38.34% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Moberg Pharma AB (publ) Operating Income for the year ending December 31, 2022 was USD -1.96 M, a 9.80% change year over year.
Moberg Pharma AB (publ) Operating Income for the year ending December 31, 2021 was USD -2.17 M, a 17.34% change year over year.
Moberg Pharma AB (publ) Operating Income for the year ending December 31, 2020 was USD -2.63 M, a -136.04% change year over year.
Moberg Pharma AB (publ) Operating Income for the year ending December 31, 2018 was USD 7.29 M, a 17.41% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Stockholm Stock Exchange: MOB.ST

Moberg Pharma AB (publ)

CEO	Ms. Anna Ljung BA, M.Sc.
IPO Date	May 26, 2011
Location	Sweden
Headquarters	GustavslundsvAegen 42
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

Key trends

Past 5 years